Noema pharma appoints michael gutch as chief financial officer

Basel, switzerland, feb. 28, 2022 (globe newswire) -- noema pharma, a swiss-based clinical stage company targeting orphan central nervous system (cns) diseases, today announces the appointment of michael gutch, ph.d., as chief financial officer. dr. gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. he served as executive director of corporate development and head of equities at astrazeneca and was most recently chief business officer and chief financial officer at entasis therapeutics, an astrazeneca spin-off, where he was involved in the company's private financing rounds, its nasdaq listing in 2018 and in the strategic partnering of its two lead programs.
ALBO Ratings Summary
ALBO Quant Ranking